An RPB researcher has found that the age of immune cells, called macrophages, may be key in determining whether damaging blood vessels will form beneath the retina and contribute to vision loss in age-related macular degeneration. A better understanding of how these macrophages work can provide potential targets for therapies to slow or even reverse vision loss. The findings are reported in the November issue of the Journal of Clinical Investigation. Read the full press release.
Age-related macular degeneration is the leading cause of blindness in the United States in people over the age of 50. It accounts for more than 40 percent of blindness among the elderly in nursing homes, and as baby boomers get older, the problem is expected to grow, with at least 8 million cases predicted by the year 2020.
